Seek Returns

ARGX vs. ROIV: argenx vs. Roivant Sciences Stock Comparison

How do argenx (ARGX) and Roivant Sciences (ROIV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

argenx (ARGX) and Roivant Sciences (ROIV) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Roivant Sciences (ROIV) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for argenx (ARGX) and Roivant Sciences (ROIV)
Profile ItemARGXROIV
Nameargenx SE American Depositary ReceiptRoivant Sciences Ltd.
Country/RegionNetherlandsUnited Kingdom
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization58.31 billion USD28.08 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateMay 18, 2017December 8, 2020
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

ARGX
ROIV
GSPC
Loading price history…
argenx (ARGX) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for argenx (ARGX) and Roivant Sciences (ROIV). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for argenx (ARGX) and Roivant Sciences (ROIV). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for argenx (ARGX) and Roivant Sciences (ROIV)
MetricARGXROIV
Total Return (1Y)11.91%96.75%
Total Return (3Y, Annualized)25.68%68.04%
Total Return (5Y, Annualized)24.22%36.73%

Risk Profile

Drawdown History

ARGX
ROIV
GSPC
Loading price history…
argenx (ARGX) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for argenx (ARGX) and Roivant Sciences (ROIV). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for argenx (ARGX) and Roivant Sciences (ROIV)
MetricARGXROIV
Volatility (1Y, Annualized)37.87%47.99%
Beta (5Y)0.451.17
Max Drawdown (5Y)-38.20%-79.22%
Avg. Volume (3M)359.84K7.82M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ARGX and ROIV are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for argenx (ARGX) and Roivant Sciences (ROIV)
MetricARGXROIV
Sharpe Ratio (1Y)0.201.93
Sortino Ratio (1Y)0.314.03

Profitability

ROE (TTM)

argenx (ARGX) has no ROE value reported for this period; Roivant Sciences (ROIV) reports a negative figure of -8.52%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
ARGX
--

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.52%

Max
109.18%
Q3
6.23%
ROIV
-8.52%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
argenx (ARGX) vs. Roivant Sciences (ROIV): ARGX does not report ROE, so it has no value marker; ROIV is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

argenx (ARGX) at 31.73% converts revenue to bottom-line profit above its industry’s benchmark range, while Roivant Sciences (ROIV) at 0.00% keeps roughly the typical share for its industry.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.73%

ARGX
31.73%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
ROIV
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
argenx (ARGX) vs. Roivant Sciences (ROIV): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile argenx (ARGX) reports 36.27%, ranking against industry peers normally.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.27%

Max
83.12%
ARGX
36.27%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-25,408.11%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
ROIV
-25,408.11%
Loading chart…
argenx (ARGX) vs. Roivant Sciences (ROIV): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for argenx (ARGX) and Roivant Sciences (ROIV)
MetricARGXROIV
ROE (TTM)---8.52%
ROA (TTM)---16.28%
Net Margin (TTM)31.73%0.00%
Operating Margin (TTM)36.27%-25,408.11%
Gross Margin (TTM)59.84%0.00%

Growth

Revenue Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Roivant Sciences (ROIV) at -71.57% is in the bottom quartile, showing a clear gap in revenue momentum.

Loading chart…
argenx (ARGX) vs. Roivant Sciences (ROIV): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: argenx (ARGX) reports EPS growth of 53.13%, ranked against its industry; Roivant Sciences (ROIV) has no EPS growth figure this period.

Loading chart…
argenx (ARGX) vs. Roivant Sciences (ROIV): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for argenx (ARGX) and Roivant Sciences (ROIV)
MetricARGXROIV
Revenue Growth (YoY)89.64%-71.57%
Revenue Growth (3Y CAGR)116.25%-36.01%
EPS Growth (YoY)53.13%--
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: Roivant Sciences (ROIV) shows current ratio of 16.72 against its industry benchmark, while argenx (ARGX) has no reading this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
Min
0.10
ARGX
--

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.72

Max
25.13
ROIV
16.72
Q3
12.13
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
argenx (ARGX) vs. Roivant Sciences (ROIV): ARGX does not report current ratio, so it has no value marker; ROIV is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

argenx (ARGX) at 0.01 keeps leverage in the lower industry quartile, while Roivant Sciences (ROIV) at 0.02 runs a more typical debt-to-equity mix.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
ARGX
0.01
Min
0.00

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max
1.42
Q3
0.65
Median
0.15
ROIV
0.02
Q1
0.02
Min
0.00
Loading chart…
argenx (ARGX) vs. Roivant Sciences (ROIV): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for argenx (ARGX) and Roivant Sciences (ROIV)
MetricARGXROIV
Current Ratio (MRQ)--16.72
Debt / Equity (MRQ)0.010.02
Net Debt / EBITDA-2.70--

Dividends

Dividend Yield (TTM)

Neither argenx (ARGX) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
argenx (ARGX) vs. Roivant Sciences (ROIV): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither argenx (ARGX) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
argenx (ARGX) vs. Roivant Sciences (ROIV): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for argenx (ARGX) and Roivant Sciences (ROIV)
MetricARGXROIV
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: argenx (ARGX) trades at 32.12 times trailing earnings, ranked against its peers, while Roivant Sciences (ROIV) has no P/E ratio this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.12

Max
85.34
Q3
43.46
ARGX
32.12
Median
26.69
Q1
13.30
Min
0.07

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
ROIV
--
Loading chart…
argenx (ARGX) vs. Roivant Sciences (ROIV): ROIV does not report P/E ratio, so it has no value marker; ARGX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

argenx (ARGX) at 9.86 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.86

Max
58.18
Q3
25.77
ARGX
9.86
Median
7.30
Q1
3.01
Min
0.01

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

3,728.61

ROIV
3,728.61
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
argenx (ARGX) vs. Roivant Sciences (ROIV): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Roivant Sciences (ROIV) at 6.64 sits in the upper P/B ratio quartile, and argenx (ARGX) at 172.23 prices even higher, above its industry range.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

172.23

ARGX
172.23
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.64

Max
13.53
ROIV
6.64
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
argenx (ARGX) vs. Roivant Sciences (ROIV): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for argenx (ARGX) and Roivant Sciences (ROIV)
MetricARGXROIV
P/E Ratio (TTM)32.12--
P/S Ratio (TTM)9.863,728.61
P/B Ratio (MRQ)172.236.64
Free Cash Flow Yield (TTM)---3.98%